Search
for

    GlossaryDrug Targets (Molecular Targets)

    specific molecules drugs interact with to produce therapeutic effects

    Drug targets, also known as pharmacological targets or therapeutic targets, are specific molecules in the body, often proteins, that drugs interact with to produce a therapeutic effect. These targets can include enzymes, receptors, ion channels, or other proteins involved in disease processes. By binding to these targets, drugs can modify their activity, leading to changes in cellular function and ultimately improving health outcomes.

    Related Terms

    Learn

    5 / 7 results

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

      learn Dutasteride

      Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity

      learn PP405

      mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

      learn SCUBE3

      a signaling molecule from dermal papilla cells being actively researched

    Research

    5 / 1000+ results

    Community Join

    5 / 388 results

      community The truth about Dutasteride (w/ sources)

      in Finasteride/Dutasteride  52 upvotes 1 year ago
      The effectiveness of Dutasteride compared to Finasteride in treating hair loss, with evidence given such as studies and experiences, as well as discussion around whether one should switch from Finasteride to Dutasteride. There is also a discussion on post-Dutasteride syndrome.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  44 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  40 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.